Phase III study of selpercatinib vs chemotherapy plus /- pembrolizumab in untreated RET positive non-small-cell lung cancer

被引：34

作者：

Solomon, Benjamin J. ^{[1
]}

Zhou, Cai Cun ^{[2
]}

Drilon, Alexander ^{[3
]}

Park, Keunchil ^{[4
]}

Wolf, Jurgen ^{[5
]}

Elamin, Yasir ^{[6
]}

Davis, Hannah M. ^{[7
]}

Soldatenkova, Victoria ^{[7
]}

Sashegyi, Andreas ^{[7
]}

Lin, Aimee Bence ^{[7
]}

Lin, Boris K. ^{[7
]}

Loong, Herbert H. ^{[8
]}

Novello, Silvia ^{[9
]}

Arriola, Edurne ^{[10
]}

Perol, Maurice ^{[11
]}

Goto, Koichi ^{[12
]}

Santini, Fernando C. ^{[13
]}

机构：

[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Shanghai Pulm Hosp, Shanghai, Peoples R China

[3] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA

[4] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[5] Univ Hosp Cologne, Ctr Integrated Oncol, Cologne, Germany

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[7] Eli Lilly & Co, Indianapolis, IN 46225 USA

[8] Chinese Univ Hong Kong, Hong Kong, Peoples R China

[9] Univ Turin, Dept Oncol, AOU San Luigi Orbassano, Turin, Italy

[10] Hosp del Mar, Barcelona, Spain

[11] Leon Berard Canc Ctr Lyon, Lyon, France

[12] Natl Canc Ctr Hosp East, Chiba, Japan

[13] Hosp Sirio Libanes, Ctr Oncol, Sao Paulo, Brazil

来源：

FUTURE ONCOLOGY | 2021年 / 17卷 / 07期

关键词：

non-small-cell lung cancer; Phase III trial; RET fusion-positive; RET kinase inhibitor; RET rearrangement; selpercatinib; targeted therapy; ALK; REARRANGEMENTS; EFFICACY; FUSIONS; IPILIMUMAB; MUTATIONS; BLOCKADE; NSCLC; EGFR; BRAF;

D O I：

10.2217/fon-2020-0935

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment-naive RET fusion-positive non-small-cell lung cancer patients in a Phase I/II clinical trial. LIBRETTO-431 (NCT04194944) is a randomized, global, multicenter, open-label, Phase III trial, evaluating selpercatinib versus carboplatin or cisplatin and pemetrexed chemotherapy with or without pembrolizumab in treatment-naive patients with locally advanced/metastatic RET fusion-positive nonsquamous non-small-cell lung cancer. The primary end point is progression-free survival by independent review. Key secondary end points include overall survival, response rate, duration of response and progression-free survival.

引用

页码：763 / 773

页数：11

共 50 条

[41] Pseudomonas aeruginosa preparation plus chemotherapy for advanced non-small-cell lung cancer: a randomized, multicenter, double-blind phase III study [J].

Chang, Jianhua ;

Liu, Yunpeng ;

Han, Baohui ;

Zhou, Caicun ;

Bai, Chunxue ;

Li, Jin .

MEDICAL ONCOLOGY, 2015, 32 (05)

[42] Pseudomonas aeruginosa preparation plus chemotherapy for advanced non-small-cell lung cancer: a randomized, multicenter, double-blind phase III study [J].

Jianhua Chang ;

Yunpeng Liu ;

Baohui Han ;

Caicun Zhou ;

Chunxue Bai ;

Jin Li .

Medical Oncology, 2015, 32

[43] Phase Ib Study of Crizotinib Plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation [J].

Patel, Sandip Pravin ;

Pakkala, Suchita ;

Pennell, Nathan A. ;

Reckamp, Karen L. ;

Lanzalone, Silvana ;

Polli, Anna ;

Tarazi, Jamal ;

Robert-Vizcarrondo, Francisco .

ONCOLOGIST, 2020, 25 (07) :562-+

[44] Impact of corticosteroids on the efficacy of first-line pembrolizumab plus chemotherapy in patients with advanced non-small-cell lung cancer [J].

Roboubi, Amytis ;

Wasielewski, Eric ;

Bordier, Soraya ;

Turlotte, Amelie ;

Pavaut, Geoffrey ;

Scherpereel, Arnaud ;

Cortot, Alexis ;

Gauvain, Clement .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17

[45] Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: A subanalysis of the phase III, randomized SATURN study [J].

Wu, Yi-Long ;

Kim, Joo-Hang ;

Park, Keunchil ;

Zaatar, Adel ;

Klingelschmitt, Gaelle ;

Ng, Christina .

LUNG CANCER, 2012, 77 (02) :339-345

[46] Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA [J].

Zeng, Xiaohui ;

Wan, Xiaomin ;

Peng, Liubao ;

Peng, Ye ;

Ma, Fang ;

Liu, Qiao ;

Tan, Chongqing .

BMJ OPEN, 2019, 9 (12) :e031019

[47] Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in RET fusion-positive non-small cell lung cancer: a case report [J].

Scattolin, Daniela ;

Scagliori, Elena ;

Scapinello, Antonio ;

Fantin, Alberto ;

Guarneri, Valentina ;

Pasello, Giulia .

FRONTIERS IN ONCOLOGY, 2023, 13

[48] Real-world evidence of efficacy of pembrolizumab plus chemotherapy and nivolumab plus ipilimumab plus chemotherapy as initial treatment for advanced non-small cell lung cancer [J].

Kaneko, Ayami ;

Kobayashi, Nobuaki ;

Miura, Kenji ;

Matsumoto, Hiromi ;

Somekawa, Kohei ;

Hirose, Tomofumi ;

Kajita, Yukihito ;

Tanaka, Anna ;

Teranishi, Shuhei ;

Sairenji, Yu ;

Kawashima, Hidetoshi ;

Yumoto, Kentaro ;

Tsukahara, Toshinori ;

Fukuda, Nobuhiko ;

Nishihira, Ryuichi ;

Watanabe, Keisuke ;

Horita, Nobuyuki ;

Hara, Yu ;

Kudo, Makoto ;

Miyazawa, Naoki ;

Kaneko, Takeshi .

THORACIC CANCER, 2024, 15 (15) :1208-1217

[49] Phase II Study of Cetuximab, Docetaxel, and Gemcitabine in Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer [J].

Spigel, David R. ;

Greco, F. Anthony ;

Thompson, Dana S. ;

Webb, Charles ;

Rubinsak, James ;

Inhorn, Roger C. ;

Reeves, James, Jr. ;

Vazquez, Elizabeth R. ;

Lane, Cassie M. ;

Burris, Howard A., III ;

Hainsworth, John D. .

CLINICAL LUNG CANCER, 2010, 11 (03) :198-203

[50] Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer [J].

Chen, Yulong ;

Yan, Bo ;

Zhang, Ran ;

Zhao, Gang ;

You, Jian .

HELIYON, 2023, 9 (09)

← 1 2 3 4 5 →